Within the next two weeks, Novo Nordisk is expected to announce the results of perhaps the most ambitious studies yet of its blockbuster GLP-1 drug semaglutide — whether the medicine can help slow the progression of Alzheimer’s disease.
The Danish company has repeatedly stressed that these are risky studies, since there hasn’t yet been definitive proof that this class of drugs, which has transformed the treatment of obesity and diabetes, can also help patients with the devastating neurological disease.
But the drugmaker still appears to be quietly preparing for the possibility that it may soon be able to add Alzheimer’s to the list of approved indications for semaglutide, marketed as Ozempic and Wegovy. Novo posted job openings just a few days ago for at least four positions around the world focused on Alzheimer’s consumer marketing and medical affairs, roles that involve communicating the scientific data behind commercial products to doctors and patients.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
